All News
The RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read Article
FDA Approves Mepolizumab for Churg-Strauss (EGPA)
The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA.
Read Article
The ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read Article
Practice Patterns of PJP Prophylaxis Among ID Physicians
While the incidence of pneumocystis pneumonia (PJP) is low is patients with rheumatologic diseases the mortality is quite high compared to PJP in patients with HIV and infection can be prevented with appropriate prophylaxis.
Read Article
Kidney transplant improves survival in GPA
Even with currently available treatment modalities, ESRD is a common complication of Granulomatosis with polyangiitis (GPA) occurring in approximately 25% of patients. Transplantation frequently used for ESRD but has not been applied widely in GPA.
Low-dose Bactrim Safe with Methotrexate in AAV
A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.
Read Article
Large Vessel Vasculitis: Giant Cell Arteritis and Takayasu Arteritis
Prof Weyland started by explaining that giant cell arteritis (GCA) and Takayasu Arteritis (TA) are granulomatous forms of arteritis.
Read Article
Necroptosis Drives Netosis and ANCA-Associated Vasculitis
PNAS reports that ANCA induced neutrophil activation, generation of neutrophil extracellular traps (NETS), and vasculitis are regulated by necroptosis. Using inhibitors of necroptosis-inducing kinases they were able to prevent ANCA associated vasculitis (AAV) in animal models.
Read Article
13 October 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!
Read Article
29 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.
Read Article
22 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.
Read Article
Rituximab Efficacy in IgG4 Related Disease
PLOS reports greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD).
Read Article
Half of Takayasu's Arteritis Relapse
A French retrospective study of 318 Takayasu's arteritis (TA) patients shows that 50% of patients will relapse and experience a vascular complication ≤10 years from diagnosis.
Read Article
15 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.
Read Article
Duration of Azathioprine Maintenance in AAV Does Not Alter Relapse Rates
A European multicentre study examined whether the duration of azathioprine (AZA) maintenance therapy in ANCA-associated vasculitis patients would influence the relapse rate during long-term follow-up.
Read Article
NEJM: Actemra Effective in Giant Cell Arteritis
On May 22, Genentech received FDA approval for the use of subcutaneous (sc) tocilizumab (TCZ) in patients with giant cell arteritis (GCA) – also known as temporal arteritis.
Read Article
Inflammatory and Autoimmune Diseases are Not Rare in HIV Patients
HIV infection and AIDs has been associated with numerous complications, presumably resulting from impaired immunity from infection. Sporadic cases and small cohorts of patients with rheumatic and autoimmune syndromes have been described but epidemiology data on the prevalence is scarce.
Read ArticleThe RheumNow Week in Review – 21 July 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com:
Read Article
Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Read Article
Actemra - First FDA Approved Drug for Giant Cell Arteritis
The FDA has approved subcutaneous tocilizumab for use in Giant Cell Arteritis based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.
Read Article
